Navigation Links
Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
Date:11/29/2011

ay control growth of neuroendocrine tumors, and an earlier Phase II study at MD Anderson showed promising anti-cancer activity for everolimus in neuroendocrine tumors.

In May of this year, an international randomized Phase III study showed everolimus improved progression-free survival in pancreatic neuroendocrine tumors, a related disease, leading to its FDA approval for treatment of those rare tumors.

Somatostatin analogues, such as octreotide, improve hormone-related symptoms associated with neuroendocrine tumors. Octreotide LAR has also shown antitumor activity, prolonging time to disease progression in patients with certain types of neuroendocrine tumors.

Increase in progression-free survival

The study, named RADIANT-2, enrolled 429 participants with low-grade or intermediate-grade advanced (unresectable locally advanced or distant metastatic) neuroendocrine tumors and a history of carcinoid syndrome. Disease progression had been established by radiological assessment within the past 12 months.

Patients were given either 10 mg per day oral everolimus or placebo, both in conjunction with 30 mg intramuscular octreotide LAR, every 28 days. Treatment was continued until disease progression, withdrawal from treatment because of adverse effects or withdrawal of consent.

Median progression-free survival by was 16.4 months in the everolimus plus octreotide LAR group and 11.2 months in the placebo plus octreotide LAR group.

Side effects were higher but manageable in the combination arm. They included stomatitis (62 percent vs. 14 percent), fatigue (31 percent vs. 23 percent) and diarrhea (27 percent vs. 16 percent).

Next steps

Yao said additional exploratory analyses to adjust for the effect of randomization imbalances will be presented at American Society of Clinical Oncology (ASCO) gastrointestinal annual meeting in 2012.

"We are working with industry sponsor [Novartis] to develop a confi
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. An important reduction in risk of stent thrombosis with everolimus-eluting stent
2. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
3. Everolimus improves progression-free survival for patients with rare pancreatic cancer
4. Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
5. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
6. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
7. How to recognize at an early stage whether a new cancer therapy prolongs life
8. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
9. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
10. Therapeutic melanoma vaccine improves response rate, progression-free survival
11. Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... better prepared to respond to an active shooter incident ... study in the journal Prehospital and Disaster Medicine ... the EMS provider comfort level with respect to entering ... neutralized or working with law enforcement personnel during that ... shooting, the Virginia Tech campus shooting, the 2009 Fort ...
(Date:7/10/2014)... with a microchip-based device developed at the Massachusetts General ... MGH Cancer Center can be cultured to establish cell ... the July 11 issue of Science , an ... reflect a tumor,s genetic mutation over time and changing ... culture cells from the blood that represent those present ...
(Date:7/10/2014)... public health concerns in the United States, with 32 ... of 2012. As health problems such as childhood obesity ... discuss the problem. , A new study, led by ... School at Washington University in St. Louis, examined the ... Twitter conversations about the issue of overweight kids. , ...
(Date:7/10/2014)... and Human Services (HHS) has announced a three-year grant ... Center totaling $4.7 million to support a new national ... cancer. , Titled "Evidence-Conformant Oncology Care," the project ... enhance care for adult cancer patients with late-stage disease, ... utilization. , "We believe that the best ...
Breaking Medicine News(10 mins):Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3
... has applauded the appeal success of the National ... National Institute for Health and Clinical Excellences (NICE) ... osteoporotic fracture, and has called for continuing efforts ... Guidance is made available. , As an ...
... Methods to identify a patient with a Do Not ... from written documentation practices to the use of color-coded ... of Hospital Medicine, a national effort to standardize color-coded ... status, allergy, fall risk, etc.), would remove current practice ...
... 18, 2007 -- The Association for Professionals ... announced a series of new educational initiatives ... include Clostridium difficile-associated disease and the three ... Medicaid Services (CMS) have classified as preventable ...
... explain why older people are prone to dehydration during ... Older adults don,t drink enough water and become dehydrated ... coordinate sensory signals about thirst, a new Australian study ... signals from the body or the interpretation of these ...
... Tampa, FL (Dec. 18, 2007) -- A University of ... treated in utero a rare but potentially devastating condition ... and can rupture during labor, leaving the baby without ... as vasa previa is frequently deadly for newborns. ...
... 2007) New research published in the December issue ... shows that outcomes of high-risk cancer operations in 80-year-olds ... published survival statistics, which may lead to unrealistic expectations ... With this limited information, elderly patients and their physicians ...
Cached Medicine News:Health News:APIC launches 'Targeting Zero' initiative to eradicate infections deemed preventable by CMS 2Health News:Lack of Strong Thirst Signals Leads Elderly to Drink Too Little 2Health News:Lack of Strong Thirst Signals Leads Elderly to Drink Too Little 3Health News:Fetal surgeon shows for first time that laser procedure may treat vasa previa 2Health News:Fetal surgeon shows for first time that laser procedure may treat vasa previa 3Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ST. LOUIS , Feb. 1 Stereotaxis (Nasdaq: ... featured Dr. Mauricio Arruda , a leading electro-physiologist ... in Cleveland, Ohio , performing a live cardiac ablation ... The patient was a 69 year old woman who suffered ...
... BRISBANE, Calif. , Feb. 1 InterMune, ... Food and Drug Administration,s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) ... for pirfenidone on March 9, 2010 .  Pirfenidone is ... idiopathic pulmonary fibrosis (IPF).   , "There is an urgent ...
Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 3InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 4InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 5
...
... Miditron Junior II ... urinalysis analyser for standardised ... hardware and software features ... high performance and convenience ...
... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...
... for four corner fusion of the capitate, ... hand. The plate is intended for use ... of function due to SLAC and SNAC ... rheumatoid arthritis. When combined with the specially ...
Medicine Products: